Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future
Lung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we re...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/16/4119 |
| _version_ | 1797524472253644800 |
|---|---|
| author | Walid Shalata Binil Mathew Jacob Abed Agbarya |
| author_facet | Walid Shalata Binil Mathew Jacob Abed Agbarya |
| author_sort | Walid Shalata |
| collection | DOAJ |
| description | Lung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we review the changes and development of treatments, with a special focus on adjuvant therapy using tyrosine kinase inhibitors (TKIs) administered to non-small-cell lung carcinoma patients who had a complete resection of the tumor harboring a mutated epidermal growth factor receptor. The clinical trials are dating from the past (chemotherapy trials), present (TKIs), and future (ongoing trials). |
| first_indexed | 2024-03-10T08:56:53Z |
| format | Article |
| id | doaj.art-d162b327191a400abd79596d4049c8b5 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T08:56:53Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d162b327191a400abd79596d4049c8b52023-11-22T07:04:04ZengMDPI AGCancers2072-66942021-08-011316411910.3390/cancers13164119Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and FutureWalid Shalata0Binil Mathew Jacob1Abed Agbarya2The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, IsraelMedical School for International Health, Ben-Gurion University of the Negev, Beer Sheva 84101, IsraelBnai Zion Medical Centre, Oncology Division and Cancer Institute, Haifa 31048, IsraelLung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we review the changes and development of treatments, with a special focus on adjuvant therapy using tyrosine kinase inhibitors (TKIs) administered to non-small-cell lung carcinoma patients who had a complete resection of the tumor harboring a mutated epidermal growth factor receptor. The clinical trials are dating from the past (chemotherapy trials), present (TKIs), and future (ongoing trials).https://www.mdpi.com/2072-6694/13/16/4119lung canceradjuvant treatmentnon-small-cell lung carcinoma (NSCLC)epidermal growth factor receptor (EGFR)tyrosine kinase inhibitor (TKI) |
| spellingShingle | Walid Shalata Binil Mathew Jacob Abed Agbarya Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future Cancers lung cancer adjuvant treatment non-small-cell lung carcinoma (NSCLC) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) |
| title | Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future |
| title_full | Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future |
| title_fullStr | Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future |
| title_full_unstemmed | Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future |
| title_short | Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future |
| title_sort | adjuvant treatment with tyrosine kinase inhibitors in epidermal growth factor receptor mutated non small cell lung carcinoma patients past present and future |
| topic | lung cancer adjuvant treatment non-small-cell lung carcinoma (NSCLC) epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) |
| url | https://www.mdpi.com/2072-6694/13/16/4119 |
| work_keys_str_mv | AT walidshalata adjuvanttreatmentwithtyrosinekinaseinhibitorsinepidermalgrowthfactorreceptormutatednonsmallcelllungcarcinomapatientspastpresentandfuture AT binilmathewjacob adjuvanttreatmentwithtyrosinekinaseinhibitorsinepidermalgrowthfactorreceptormutatednonsmallcelllungcarcinomapatientspastpresentandfuture AT abedagbarya adjuvanttreatmentwithtyrosinekinaseinhibitorsinepidermalgrowthfactorreceptormutatednonsmallcelllungcarcinomapatientspastpresentandfuture |